Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Blood Cancer Journal|October 24, 2025
Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significanceElena Alejo, Verónica González-Calle, Patricia Blázquez, et al.
Hemasphere|November 15, 2019
Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple MyelomaVíctor Higuero Saavedra, Verónica González-Calle, Eduardo Sobejano, et al.
Blood Cancer Journal|March 20, 2023
Multiple myeloma with t(11;14): impact of novel agents on outcomeBorja Puertas, Verónica González-Calle, Eduardo Sobejano-Fuertes, et al.
Medicine|May 11, 2017
Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone: A case reportAna María Cubo, Zandra Mileny Soto, Miguel Ángel Cruz, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
European Journal of Haematology|April 24, 2024
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE studyHans C Lee, Karthik Ramasamy, Margaret Macro, et al.
Haematologica|November 9, 2014
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myelomaBruno Paiva, Mauricio Chandia, Noemi Puig, et al.
Blood Advances|May 8, 2024
A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myelomaBorja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, et al.
Molecular Oncology|July 17, 2025
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulationIgnacio J Cardona-Benavides, Sara Cristobal-Vargas, Cristina De Ramón, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Blood Cancer Journal|October 24, 2025
Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significanceElena Alejo, Verónica González-Calle, Patricia Blázquez, et al.
Hemasphere|November 15, 2019
Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple MyelomaVíctor Higuero Saavedra, Verónica González-Calle, Eduardo Sobejano, et al.
Blood Cancer Journal|March 20, 2023
Multiple myeloma with t(11;14): impact of novel agents on outcomeBorja Puertas, Verónica González-Calle, Eduardo Sobejano-Fuertes, et al.
Medicine|May 11, 2017
Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone: A case reportAna María Cubo, Zandra Mileny Soto, Miguel Ángel Cruz, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
European Journal of Haematology|April 24, 2024
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE studyHans C Lee, Karthik Ramasamy, Margaret Macro, et al.
Haematologica|November 9, 2014
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myelomaBruno Paiva, Mauricio Chandia, Noemi Puig, et al.
Blood Advances|May 8, 2024
A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myelomaBorja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, et al.
Molecular Oncology|July 17, 2025
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulationIgnacio J Cardona-Benavides, Sara Cristobal-Vargas, Cristina De Ramón, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Pageof 9